Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oligonucleotide therapeutics for human leukaemia

A M Gewirtz1

  • 1Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Ciba Foundation Symposium
|January 1, 1997
PubMed
Summary

Antisense oligonucleotides show promise for gene-targeted therapies, despite controversies. Further research into their mechanisms and clinical application is needed for successful drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Interleukin-1 α and Interleukin-1 β on Erythroid Progenitor Cell Growth in Serum Free Cultures: An In Vitro Study Relevant to the Pathogenesis of the Anemia of Chronic Disease.

Hematology (Amsterdam, Netherlands)·2016
Same author

Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.

Leukemia·2012
Same author

Delivery and mechanistic considerations for the production of knock-in mice by single-stranded oligonucleotide gene targeting.

Gene therapy·2006
Same author

Progress in the development of nucleic acid therapeutics.

Handbook of experimental pharmacology·2006
Same author

2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing.

Nucleic acids research·2006
Same author

Rationally targeted, conformationally constrained, oxetane-modified oligonucleotides demonstrate efficient gene-silencing activity in a cellular system.

Annals of the New York Academy of Sciences·2006

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Genetics

Background:

  • Antisense oligonucleotide (ASO) therapeutics have faced significant controversy regarding their mechanism of action, reliability, and clinical utility.
  • Development has been marked by hype, leading to unmet expectations from proponents.
  • Despite challenges, some gene disruption successes using ASOs have been validated through rigorous scientific scrutiny.

Purpose of the Study:

  • To address the controversies surrounding antisense oligonucleotide therapeutics.
  • To highlight the potential of gene-targeted drugs for specific and low-toxicity treatments.
  • To advocate for increased research into ASO mechanisms and clinical applications.

Main Methods:

  • Review of existing literature on antisense oligonucleotide therapeutics.
  • Case study of c-myb as a validated gene target for antisense technology.
  • Analysis of the potential benefits and challenges in clinical translation.

Main Results:

  • Notable successes in gene disruption using antisense oligonucleotide technology have been achieved and rigorously validated.
  • The c-myb gene target serves as a case study demonstrating the potential of this approach.
  • Antisense oligonucleotides offer the promise of high specificity and low toxicity in drug development.

Conclusions:

  • Antisense oligonucleotides represent a paradigm of rational drug development with potential for specific gene targeting.
  • Despite ongoing challenges, the potential benefits of antisense oligonucleotide therapeutics warrant continued research.
  • Increased efforts are crucial to fully understand ASO mechanisms and optimize their clinical application.

Related Experiment Videos